BioSpace News Archive

The global Transdermal Patch market size is estimated to be worth US$ 6793 million in 2021 and is forecast to a readjusted size of US$ 8726.9 million by 2028 with a CAGR of 3.6% during the forecast period 2022-2030.

The global Rabies Vaccine market size is estimated to be worth US$ 931 million in 2021 and is forecast to a readjusted size of US$ 1229.1 million by 2028 with a CAGR of 4.0% during the forecast period 2022-2030.

The global Hydroxycarbamide market size is estimated to be worth US$ 233 million in 2021 and is forecast to a readjusted size of US$ 342.7 million by 2028 with a CAGR of 5.6% during the forecast period 2022-2030.

Data Bridge Market Research presents a research report and top winning strategies for the Elderly Care Market. Best subject matter experts, researchers, and market research professionals organized this report in order to ensure that the information in it is compiled from the most authentic sources and that the forecast is of the highest accuracy.

Data Bridge Market Research adds “Global Sleep Apnea Devices Market Share, Size, Trends and Forecast Market Research Report” reports to its database. Sleep Apnea Devices market report has been produced by focusing on several factors of the present and upcoming market scenario.

Icosavax, Inc. (Nasdaq: ICVX), today announced positive topline interim results from its Phase 1/1b clinical trial of IVX-121, a VLP displaying a prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen, in young and older adults.

Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications.

Beyond Air, Inc. (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has approved LungFit® PH to treat term and near-term neonates with hypoxic respiratory failure (often referred to as persistent pulmonary hypertension of the newborn or PPHN) (prescription use only).

Oyster Point Pharma, Inc. announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization.

89bio, Inc. announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase shares of its common stock.